


Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 02/01/2022
Policy Number: PA.CP.PHAR.203	Effective Date: 01/01/2018 Revision Date: 01/2022
Policy Name: Cosyntropin (Cortrosyn)	
<p>Type of Submission – <u>Check all that apply:</u></p> <p> <input type="checkbox"/> New Policy <input type="checkbox"/> Revised Policy* <input checked="" type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> </p>	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any changes or clarifying information for the policy below:</p> <p>1Q 2022 annual review: added generic redirection for Cortrosyn requests; references reviewed and updated</p>	
Name of Authorized Individual (Please type or print): Venkateswara R. Davuluri, MD	Signature of Authorized Individual: 

Clinical Policy: Cosyntropin (Cortrosyn)

Reference Number: PA.CP.PHAR.203

Effective Date: 01/2018

Last Review Date: 01/2022

[Coding Implications](#)
[Revision Log](#)

Description

Cosyntropin (Cortrosyn[®]) is a synthetic subunit of adrenocorticotrophic hormone (ACTH).

FDA Approved Indication(s)

Cortrosyn is indicated for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Policy/Criteria

It is the policy of health plans affiliated with Pennsylvania Health and Wellness that cosyntropin and Cortrosyn are **medically necessary** when one of the following criteria are met:

I. Initial Approval Criteria

A. Presumed Adrenocortical Insufficiency (must meet all):

1. Prescribed for the diagnostic testing of adrenocortical insufficiency;
2. If Cortrosyn is requested, member must use generic cosyntropin, unless contraindicated or clinically significant adverse effects are experienced;
3. Dose of Cortrosyn does not exceed one of the following (a or b):
 - a. If ≤ 2 years: 0.25 mg per dose (1 vial);
 - b. If > 2 years: 0.75 mg per dose (3 vials);

Approval duration: 1 dose

B. Other diagnoses/indications: Refer to PA.CP.PMN.53

II. Continued Approval

A. Presumed Adrenocortical Insufficiency:

1. Re-authorization is not permitted. Member must be evaluated against the initial approval criteria.

Approval duration: Not applicable

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit and documentation supports positive response to therapy or the Continuity of Care Policy (PA.LTSS.PHAR.01) applies;

Approval duration: Duration of request or 3 months (whichever is less); or

2. Refer to PA.CP.PMN.53

III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ACTH: adrenocorticotrophic hormone

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): history of previous adverse reaction to Cortrosyn, synthetic ACTH, or to any of the excipients.
- Boxed warning(s): none reported

IV. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Diagnostic testing of adrenal insufficiency	0.25-0.75 mg IV or IM; in pediatric patients ≤ 2 years, 0.125 mg will often suffice	0.75 mg/dose

V. Product Availability

Vial for injection: 0.25 mg

VI. References

1. Cosyntropin Prescribing Information. Princeton, NJ: Sandoz Inc. May 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022028s005lbl.pdf Accessed September 20, 2021.
2. Cortrosyn Prescribing Information. Rancho Cucamonga, CA. Amphastar Pharmaceuticals, Inc.; September 2010. Available at <http://www.cortrosyn.com>. Accessed September 20, 2021.
3. Cosyntropin Drug Monograph. Clinical Pharmacology. Tampa, FL: Gold Standard Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com>. Accessed September 20, 2021.
4. Bornstein, S, Allolio B, Arlt, Wiebke, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. Feb 2016; 101(2): 364-389.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
J0833	Injection, cosyntropin, not otherwise specified, 0.25 mg
J0834	Injection, cosyntropin (Cortrosyn), 0.25 mg

Reviews, Revisions, and Approvals	Date	Approval Date
Modified max dose criteria from 0.125 mg to 0.25 mg for age ≤ 2 years since 0.125 is not a true max per labeling, plus partial vials cannot be dispensed so a dose of 0.125 is unenforceable post-approval. References reviewed and updated.	02/18	

Reviews, Revisions, and Approvals	Date	Approval Date
1Q 2019 annual review: references reviewed and updated	01/19	
1Q 2020 annual review: references reviewed and updated.	01/20	
1Q 2021 annual review: references reviewed and updated.	01/21	
1Q 2022 annual review: added generic redirection for Cortrosyn requests; references reviewed and updated	01/2022	